MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1

Jiang,Feng; Yu,Qiuhua; Chu,Ying; Zhu,Xiaobo; Lu,Wenbin; Liu,Qian; Wang,Qiang

doi:10.3892/ijo.2018.4610

MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1

Authors:
- Feng Jiang
- Qiuhua Yu
- Ying Chu
- Xiaobo Zhu
- Wenbin Lu
- Qian Liu
- Qiang Wang
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Wujin People's Hospital of Changzhou, Changzhou, Jiangsu 213017, P.R. China, Central Laboratory, Wujin People's Hospital of Changzhou, Changzhou, Jiangsu 213017, P.R. China, Department of Oncology, Wujin People's Hospital of Changzhou, Changzhou, Jiangsu 213017, P.R. China
Published online on: October 29, 2018 https://doi.org/10.3892/ijo.2018.4610
Pages: 128-138
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs or miRs) have recently emerged as key regulators of various types of cancer, including non‑small cell lung cancer (NSCLC). The disrupted expression of miRNAs is associated with tumorigenesis and metastasis; however, the underlying mechanisms remain unclear. In this study, we demonstrate that miR‑98‑5p is downregulated in NSCLC and that miR‑98‑5p deficiency is associated with an advanced clinical stage and metastasis. A dual‑luciferase reporter assay was performed to confirm that transforming growth factor beta receptor 1 (TGFBR1), a key stimulator of tumor proliferation and metastasis, was a direct target of miR‑98‑5p. miR‑98‑5p overexpression resulted in the downregulation of TGFBR1 and the suppression of the viability, proliferation, migration and invasion of A549 and H1299 cells. Furthermore, miR‑98‑5p was demonstrated to be an efficient suppressor of tumor growth in an A549 subcutaneous xenograft tumor mouse model. Finally, miR‑98‑5p overexpression exerted a significant anti‑metastatic effect in a mouse model of pulmonary metastasis. On the whole, the results of the present study suggest that miR‑98‑5p/TGFBR1 may serve as promising targets for NSCLC therapy.

View Figures

View References

1	Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, et al: Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 11:613–638. 2016. View Article : Google Scholar : PubMed/NCBI
2	Gupta GP and Massagué J: Cancer metastasis: Building a framework. Cell. 127:679–695. 2006. View Article : Google Scholar : PubMed/NCBI
3	Hsiao SH, Chung CL, Chou YT, Lee HL, Lin SE and Liu HE: Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases. Lung Cancer. 82:319–323. 2013. View Article : Google Scholar : PubMed/NCBI
4	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ardizzoni A, Tiseo M, Boni L, Di Maio M, Buffoni L, Belvedere O, Grossi F, D’Alessandro V, de Marinis F, Barbera S, et al: Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC. Lung Cancer. 100:30–37. 2016. View Article : Google Scholar : PubMed/NCBI
6	Zhao Z, Su Z, Zhang W, Luo M, Wang H and Huang L: A randomized study comparing the effectiveness of microwave ablation radioimmunotherapy and postoperative adjuvant chemoradiation in the treatment of non-small cell lung cancer. J BUON. 21:326–332. 2016.PubMed/NCBI
7	Hall RD, Le TM, Haggstrom DE and Gentzler RD: Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 4:515–523. 2015.PubMed/NCBI
8	John B, Enright AJ, Aravin A, Tuschl T, Sander C and Marks DS: Human MicroRNA targets. PLoS Biol. 2:e3632004. View Article : Google Scholar : PubMed/NCBI
9	Tutar L, Tutar E, Özgür A and Tutar Y: Therapeutic Targeting of microRNAs in Cancer: Future Perspectives. Drug Dev Res. 76:382–388. 2015. View Article : Google Scholar : PubMed/NCBI
10	Sethi S, Ali S, Sethi S and Sarkar FH: MicroRNAs in personalized cancer therapy. Clin Genet. 86:68–73. 2014. View Article : Google Scholar : PubMed/NCBI
11	Monroig PC, Chen L, Zhang S and Calin GA: Small molecule compounds targeting miRNAs for cancer therapy. Adv Drug Deliv Rev. 81:104–116. 2015. View Article : Google Scholar
12	Kane NM, Thrasher AJ, Angelini GD and Emanueli C: Concise review: MicroRNAs as modulators of stem cells and angiogenesis. Stem Cells. 32:1059–1066. 2014. View Article : Google Scholar : PubMed/NCBI
13	Vira D, Basak SK, Veena MS, Wang MB, Batra RK and Srivatsan ES: Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 31:733–751. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sun X, Jiao X, Pestell TG, Fan C, Qin S, Mirabelli E, Ren H and Pestell RG: MicroRNAs and cancer stem cells: The sword and the shield. Oncogene. 33:4967–4977. 2014. View Article : Google Scholar
15	Liu Y, Li M, Zhang G and Pang Z: MicroRNA-10b overexpression promotes non-small cell lung cancer cell proliferation and invasion. Eur J Med Res. 18:412013. View Article : Google Scholar : PubMed/NCBI
16	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
17	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
18	Ni R, Huang Y and Wang J: miR-98 targets ITGB3 to inhibit proliferation, migration, and invasion of non-small-cell lung cancer. Onco Targets Ther. 8:2689–2697. 2015.PubMed/NCBI
19	Jiang P, Wu X, Wang X, Huang W and Feng Q: NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget. 7:43337–43351. 2016.PubMed/NCBI
20	Siragam V, Rutnam ZJ, Yang W, Fang L, Luo L, Yang X, Li M, Deng Z, Qian J, Peng C, et al: MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-4 and matrix metalloproteinase-11. Oncotarget. 3:1370–1385. 2012. View Article : Google Scholar : PubMed/NCBI
21	Jinushi T, Shibayama Y, Kinoshita I, Oizumi S, Jinushi M, Aota T, Takahashi T, Horita S, Dosaka-Akita H and Iseki K: Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 3:1544–1552. 2014. View Article : Google Scholar : PubMed/NCBI
22	Yang G, Zhang X and Shi J: MiR-98 inhibits cell proliferation and invasion of non-small cell carcinoma lung cancer by targeting PAK1. Int J Clin Exp Med. 8:20135–20145. 2015.
23	Chen X, Xu Y, Liao X, Liao R, Zhang L, Niu K, Li T, Li D, Chen Z, Duan Y, et al: Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumour Biol. 37:11927–11936. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhou H, Huang Z, Chen X and Chen S: miR-98 inhibits expression of TWIST to prevent progression of non-small cell lung cancers. Biomed Pharmacother. 89:1453–1461. 2017. View Article : Google Scholar : PubMed/NCBI
25	Pasche B, Pennison MJ, Jimenez H and Wang M: TGFBR1 and cancer susceptibility. Trans Am Clin Climatol Assoc. 125:300–312. 2014.PubMed/NCBI
26	Wang H, Zhang Q, Wang B, Wu W, Wei J, Li P and Huang R: miR-22 regulates C2C12 myoblast proliferation and differentiation by targeting TGFBR1. Eur J Cell Biol. 97:257–268. 2018. View Article : Google Scholar : PubMed/NCBI
27	Yu F, Chen B, Fan X, Li G, Dong P and Zheng J: Epigenetically-Regulated MicroRNA-9-5p Suppresses the Activation of Hepatic Stellate Cells via TGFBR1 and TGFBR2. Cell Physiol Biochem. 43:2242–2252. 2017. View Article : Google Scholar : PubMed/NCBI
28	Cheng R, Dang R, Zhou Y, Ding M and Hua H: MicroRNA-98 inhibits TGF-β1-induced differentiation and collagen production of cardiac fibroblasts by targeting TGFBR1. Hum Cell. 30:192–200. 2017. View Article : Google Scholar : PubMed/NCBI
29	Rosman DS, Phukan S, Huang CC and Pasche B: TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation. Cancer Res. 68:1319–1328. 2008. View Article : Google Scholar : PubMed/NCBI
30	Zhou R, Huang Y, Cheng B, Wang Y and Xiong B: TGFBR1*6A is a potential modifier of migration and invasion in colorectal cancer cells. Oncol Lett. 15:3971–3976. 2018.PubMed/NCBI
31	Mody HR, Hung SW, Pathak RK, Griffin J, Cruz-Monserrate Z and Govindarajan R: miR-202 diminishes TGFβ receptors and attenuates TGFβ1-Induced EMT in pancreatic cancer. Mol Cancer Res. 15:1029–1039. 2017. View Article : Google Scholar : PubMed/NCBI
32	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
33	Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar :
34	Berindan-Neagoe I, Monroig PC, Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
35	Akhurst RJ and Hata A: Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov. 11:790–811. 2012. View Article : Google Scholar : PubMed/NCBI
36	Bierie B and Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 6:506–520. 2006. View Article : Google Scholar : PubMed/NCBI
37	Sethi N, Dai X, Winter CG and Kang Y: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19:192–205. 2011. View Article : Google Scholar : PubMed/NCBI
38	Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL and Massagué J: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA. 102:13909–13914. 2005. View Article : Google Scholar : PubMed/NCBI
39	Attili I, Karachaliou N, Bonanno L, Berenguer J, Bracht J, Codony-Servat J, Codony-Servat C, Ito M and Rosell R: STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Ther Adv Med Oncol. Apr 2–2018.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
40	Reis H, Metzenmacher M, Goetz M, Savvidou N, Darwiche K, Aigner C, Herold T, Eberhardt WE, Skiba C, Hense J, et al: MET expression in advanced non-small-cell lung cancer: Effect on clinical outcomes of chemotherapy, targeted therapy, and immunotherapy. Clin Lung Cancer. 19:e441–e463. 2018. View Article : Google Scholar : PubMed/NCBI
41	Yang H, Yan L, Sun K, Sun X, Zhang X, Cai K and Song T: LncRNA BCAR4 increases viability, invasion and migration non-small cell lung cancer cells by targeting glioma-associated oncogene 2 (GLI2). Oncol Res. Apr 3–2018.Epub ahead of print. View Article : Google Scholar
42	Ambros V: MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
43	Liu W, Xiao P, Wu H, Wang L, Kong D and Yu F: MicroRNA-98 plays a suppressive role in non-small cell lung cancer through inhibition of SALL4 protein expression. Oncol Res. 25:975–988. 2017. View Article : Google Scholar
44	Wang MJ, Zhang H, Li J and Zhao HD: microRNA-98 inhibits the proliferation, invasion, migration and promotes apoptosis of breast cancer cells by binding to HMGA2. Biosci Rep. 38:BSR201805712018. View Article : Google Scholar : PubMed/NCBI
45	Cai C, Huo Q, Wang X, Chen B and Yang Q: SNHG16 contributes to breast cancer cell migration by competitively binding miR-98 with E2F5. Biochem Biophys Res Commun. 485:272–278. 2017. View Article : Google Scholar : PubMed/NCBI